Search

Meeting Coverage:

EURETINA Congress

EURETINA: 2018

Trials on Steroids for Diabetic Eye Disease

Albert J. Augustin, MD

Show Description +

Albert J. Augustin, MD, discusses the BEVORDEX trial, which compared bevacizumab (Avastin, Genentech) with the dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan). Dr. Augustin also shares the results of studies that evaluated the efficacy of switching from anti-VEGF therapy to either the dexamethasone implant or the fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien, Alimera Science) in cases of recalcitrant disease.

Posted: 9/21/2018

Keywords:

Anti-VEGF

•

Diabetic macular edema, DME

•

Steroids

Up Next

Is There Any Hope for Dry AMD Patients?

Is There Any Hope for Dry AMD Patients?

Anat Loewenstein, MD, William Tucker, MD

Understanding the ALTAIR Study

Understanding the ALTAIR Study

Masahito Ohji, MD

Three Exciting New Drugs

Three Exciting New Drugs

Pravin U. Dugel, MD

Value of Recent Surgical Innovations

Value of Recent Surgical Innovations

José García-Arumí, MD, PhD

The One Thing Every Doctor Can Do to Improve Efficiency in the Office

The One Thing Every Doctor Can Do to Improve Efficiency in the Office

Nadia K. Waheed, MD, MPH, Pravin U. Dugel, MD

Disrupted Imaging on OCTA

Disrupted Imaging on OCTA

Nadia K. Waheed, MD, MPH

Micropulse Laser in BRVO

Micropulse Laser in BRVO

Matteo Forlini, MD

Gene Therapy in Retinitis Pigmentosa

Gene Therapy in Retinitis Pigmentosa

Robert E. MacLaren, MB, ChB, DPhil, FRCOphth, FRCS, FACS, FMedSci

Can We Get Smaller Than 27-Gauge Instrumentation?

Can We Get Smaller Than 27-Gauge Instrumentation?

José García-Arumí, MD, PhD, Robert E. MacLaren, MB, ChB, DPhil, FRCOphth, FRCS, FACS, FMedSci

Can Technology Lead to a Seamless Diagnosis?

Can Technology Lead to a Seamless Diagnosis?

William Tucker, MD

Management of RVO

Management of RVO

Anat Loewenstein, MD

Back to All Videos

Trials on Steroids for Diabetic Eye Disease

Albert J. Augustin, MD

Albert J. Augustin, MD, discusses the BEVORDEX trial, which compared bevacizumab (Avastin, Genentech) with the dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan). Dr. Augustin also shares the results of studies that evaluated the efficacy of switching from anti-VEGF therapy to either the dexamethasone implant or the fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien, Alimera Science) in cases of recalcitrant disease.

Posted: 9/21/2018

Keywords:

Anti-VEGF

•

Diabetic macular edema, DME

•

Steroids

Please log in to leave a comment.

More From EURETINA: 2018 Coverage

Understanding the ALTAIR Study

Understanding the ALTAIR Study

Masahito Ohji, MD

Three Exciting New Drugs

Three Exciting New Drugs

Pravin U. Dugel, MD

Value of Recent Surgical Innovations

Value of Recent Surgical Innovations

José García-Arumí, MD, PhD

The One Thing Every Doctor Can Do to Improve Efficiency in the Office

The One Thing Every Doctor Can Do to Improve Efficiency in the Office

Nadia K. Waheed, MD, MPH, Pravin U. Dugel, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of EURETINA: 2018.